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Cellular senescence is a barrier to tumorigenesis in normal cells, and tumor cells undergo senescence responses
to genotoxic stimuli, which is a potential target phenotype for cancer therapy. However, in this setting, mixed-
mode responses are common with apoptosis the dominant effect. Hence, more selective senescence inducers
are required. Here we report a machine learning–based in silico screen to identify potential senescence agonists.
We built profiles of differentially affected biological process networks from expression data obtained under
induced telomere dysfunction conditions in colorectal cancer cells and matched these to a panel of 17 protein
targets with confirmatory screening data in PubChem. We trained a neural network using 3517 compounds
identified as active or inactive against these targets. The resulting classification model was used to screen a virtual
library of ~2M lead-like compounds. One hundred and forty-seven virtual hits were acquired for validation in
growth inhibition and senescence-associated β-galactosidase assays. Among the found hits, a benzimidazolone
compound, CB-20903630, had low micromolar IC50 for growth inhibition of HCT116 cells and selectively induced
senescence-associated β-galactosidase activity in the entire treated cell population without cytotoxicity or
apoptosis induction. Growth suppression was mediated by G1 blockade involving increased p21 expression and
suppressed cyclin B1, CDK1, and CDC25C. In addition, the compound inhibited growth of multicellular spheroids
and caused severe retardation of population kinetics in long-term treatments. Preliminary structure-activity and
structure clustering analyses are reported, and expression analysis of CB-20903630 against other cell cycle
suppressor compounds suggested a PI3K/AKT-inhibitor–like profile in normal cells, with different pathways
affected in cancer cells.
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Cellular senescence in normal cells is an irreversible cell cycle arrest
which is involved in cellular aging and tissue maintenance, and
which is induced by critically shortened telomeres at the end of
replicative lifespan. Oxidative damage and oncogene activation
accelerate both telomere shortening and senescence induction [1].
Therefore, senescence is considered to be a barrier to tumorigenesis
which cancer cells must bypass to acquire a transformed phenotype
[2,3].
Many cancer cells retain the capacity to undergo senescence-like
growth arrest in response to agents including chemotherapeutics and
ionizing radiation in addition to many targeted agents [4]. Hence,
despite inactivation of some key pathways, many tumor cells retain
the ability to exit the cell cycle under appropriate treatments. Thus,
latent senescence signaling may persist in tumors [5].
There is substantial interest in senescence induction as a
therapeutic outcome in cancer. However, senescence involves
multiple processes including telomere homeostasis, DNA damage
and inflammatory signaling, chromatin regulation, and metabolism
[6,7]. Interaction of these with the diverse mutational backgrounds of
cancer cells adds further complexity in attempting to define the best
targets for therapeutic intervention. It seems likely that a spectrum of
senescence-like responses is possible in cancer cells depending on
induction agent and signaling environment [8,9].
Given limitations in current knowledge, phenotypic screening is
attractive both for compound and pathway discovery focused on
senescence [10–12]. Suitable phenotypic markers for assay develop-
ment include p21 and p16 levels, the senescence-associated secretory
phenotype, senescence-associated β-galactosidase (SA-β-gal) staining,
senescence-associated heterochromatin foci, and altered morphology
[1]. However, although many agents elicit senescence, responses
obtained are often restricted to subsets of cells, with apoptotic cell
death dominant [13].
To evaluate senescence induction as an anticancer modality will
require identification of senescence agonists which are substantially
more selective than currently available tools [14]. Without detailed
knowledge of targets, the screening challenge is not simply
identification of compounds which can cause senescence; rather,
stratification of the most selective compounds among many expected
partial actives is critical. Identification of enriched libraries would be
beneficial before initiating a screening campaign. We reasoned that
virtual screening might identify such an enriched set.
Ligand-based virtual screening is of increasing interest in the
construction of activity models, ranging from well-defined target
binding studies [15] to more complex scenarios such as modeling of
experimental microsomal stability results [16], and a wide variety of
platforms and datasets are now available [17]. Another major goal is to
identify new compounds with activity against a given target based on
feature recognition [18].
In either case, abstraction of chemical structure information into a
set of numerical descriptors is critical. These must provide detailed
representation of the chemical and property space for a given
compound set [19]. An assumption is that a relation can be made
between these “fingerprints” and a classifier (active/inactive) or
known quantity such as IC50. Machine learning methods such as
neural networks [18,20] or support vector machines [21,22] provide a
powerful approach. Feature recognition rules are learned from a
training set with known activity; trained models are then simulated
against a new compound set of unknown activity.Here we report a virtual screen using an artificial neural network
ensemble trained by the scaled conjugate gradient descent method
[23] using compounds identified from pooled PubChem screens
[24,25] against a panel of senescence-related targets. Targets were
selected by matching available screens to cellular “process networks
profiles” obtained by functional enrichment analysis of expression data
in colorectal cancer cells with induced telomere dysfunction. The
trained ensemble was used to classify a library of around 2M lead-like
compounds, leading to identification of a benzimidazolone compound
with lowmicromolar IC50 which selectively induces G1 blockade and
SA-β-gal without causing apoptosis. Preliminary structure/activity
relationships (SARs) and clustering studies are reported.
Results
Identification of a Senescence-Associated Protein Target Panel
Ad-hTR-mut is an adenoviral vector harboring mutant telomere
template sequence [2,26]. Telomerase-dependent reverse transcription
in cancer cells incorporatesmutant sequence in the telomeres of infected
cells, causing rapid telomere damage signaling. This provides a highly
selective way to induce telomere dysfunction and cellular senescence.
To identify pathways associated with telomere dysfunction and
senescence, we performed expression profiling and pathway analysis
[27–29] on HCT116 colorectal cancer cells infected with Ad-hTR-mut
or treated in long-term culture with telomerase inhibitor GRN163L
[30,31]. “Process network profiles” were generated by pathway
enrichment analysis against 169 curated networks from the MetaCore
database [27] covering 23 top-level processes (Supplementary Table S1).
Heat maps were generated based on significance of each network to
visualize overall significance of each process (Figure 1A and Supplemen-
tary Figure S1). The most significant enrichments of differentially
expressed genes in response to telomere targeting agents were on
networks involved in DNA damage, cell cycle, and protein folding.
We hypothesized that targets involved in these telomere
dysfunction processes would be good candidate targets for senescence
induction. We therefore sought to identify a target group with known
involvement in these processes and for which confirmatory
(dose-response) screening results were available within the PubChem
bioassay database [24,25]. In searching available screens, we identified
17 candidate protein targets with relevance to these processes and
with associated confirmatory screens (Table 1).
Enrichment analysis on this target list confirmed close involvement
of the panel in the same process networks identified as significantly
affected by telomere targeting (Figure 1A and Supplementary Figure
S1). We also performed shortest-paths analysis of the target panel in
MetaCore to determine functional relations between these targets
(Figure 1B). These targets participate in a closely connected direct
interactions network, indicating the close interplay between diverse
processes in senescence regulation.
Development of a Senescence-Targeted Virtual Screen
The overall neural network optimization workflow is shown in
Supplementary Figure S2. To develop the classifier, compound sets
associated with each identified PubChem bioassay were merged into
active and inactive pools (Table 1). As classification models can be
affected by an initial unbalance in the data, we aimed at retaining
similar compound numbers in each list. Similarity filters were applied
to reduce the size of very large inactive lists using ChemOffice. The
pooled lists were cleaned, duplicates were removed, and a molecular
Figure 1. Development of a senescence-targeted virtual screen. (A) Expression microarray data from colorectal cancer cells were used to
generate process network profiles of induced telomere dysfunction. Top scoring processes are shown. The complete profile is given in
Supplementary Figure S1. Processes in red scored as significant. Numbers in each cell are the hypergeometric P value for each gene list
against each process network. The main processes affected were matched to targets involved in those processes for which confirmatory
screens were available in PubChem. (B) Interactions in the senescence-associated target panel network identified by direct-interactions
network building in GeneGo. (C) Diversity of the 3517-compound training set. Principal component analysis was performed on the 495
selected chemical descriptors, and projections on the first three principal components were visualized in Matlab. Actives are shown in
blue; inactives are shown in red. (D) Structure of the trained networks. A 10-network ensemble was used for the virtual screen.
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inactives were then merged to generate the training set, and duplicates
arising after the merge were excluded. The more balanced training set
contained 3924 compounds of which 1859 were active against the
targets panel and 2065 were inactive.
For each compound, 2780 descriptors were generated. These
included 729 1D/2D descriptors, 880 PubChem fingerprints and
1024 CDK extended fingerprints obtained using PaDel, and 147
pharmacophore fingerprints obtained using PowerMV [32,33]. An
initial parameter scan was performed on this training set to identify
the classifier performance when learning rule and neuron number
were varied (Supplementary Figure S3). The best initial parameter set(20 neurons, 1 hidden layer, with learning by scaled conjugate
descent) gave 73.8% classification accuracy with Cohen’s κ = 0.51
[34] in 10-fold cross-validation. To improve the performance, we
excluded the compounds that were most consistently misclassified
under these parameters (Mean Square Error N 0.4 excluded). A total
of 3536 compounds were retained, and a features selection protocol
(see methods) was performed on the descriptor set for these. Nineteen
compounds were not correctly recognized by the feature selection
software and were excluded.
We retained 495 descriptors for the final 3517 compound set.
Principal component analysis on these descriptors is shown in
Figure 1C, illustrating good overlap between the active and inactive
Table 1. Selected PubChem Bioassay Target Panel and Associated Compounds Identified as Relevant to Telomere-Dysfunction Process Network Profiles Generated in HCT116 Cells
Target PubChem AID Actives Inactives Description
p21 N/A 29 29 In-house screening data. Luciferase assay for activation of p21 promoter activity; inactives 50%-85% similarity with actives.
p53 624305 296 405 Confirmatory luciferase assay for activation of p53-dependent synthetic promoter reporter.
WEE1 1410 39 147 Increased WEE1-luciferase fusion gene activity; inactives 65% similarity to actives.
INCENP 473665 8 0 Small series of aurora inhibitors based on modification of an existing clinical candidate.
IL8 651758 38 88 Time-resolved FRET assay (IF) for IL8 secretion from cells; inactives 65% similarity to actives.
ATM 493192 41 36 Confirmatory ELISA for phosphorylation of ATM target protein.
MTORC1 2668 49 0 Confirmatory cell-based IF assay for phospho-rpS6.
HSP90 712 91 173 Confirmatory FP assay for HSP90 binding.
DNMT1 602386 179 21 Confirmatory fluorescein-labeled DNA oligomethylation assay.
BLM 2585 83 55 Confirmatory fluorescence quench DNA unwinding assay.
MDM2 1394 41 159 Confirmatory MDM2-luc autoubiquitination assay.
RECQL1 2708 173 321 Confirmatory fluorescence quench DNA unwinding assay.
SENP1 651697 117 60 Confirmatory kinetic FRET assay for SENP protease inhibition.
VDR 602201 159 115 Confirmatory FP assay for interaction of VDR and coregulator peptide.
EIF4E 855 77 486 Confirmatory TR-FRET for association of EIF4E/EIF4G.
RAD54 651657 394 63 Confirmatory fluorescent HR assay.
JMJD2A 488840 43 0 Confirmatory dissociation enhanced lanthanide fluorescence assay.
WEE1, homologue of S.Pombe Wee1; INCENP, Inner Centromere Protein; IL8, Interleukin 8; ATM, Ataxia Telangiectasia Mutated; MTORC1, Mammalian Target of Rapamycin Complex 1; HSP90, Heat Shock
Protein (90kDa);DNMT1,DNAMethyl Transferase 1; BLM,BloomSyndrome;MDM2,MouseDoubleMinute 2 homologue; RECQL1, E.Coli RecQLike helicase 1; SENP1, Sentrin Specific Protease familymember
1; VDR, Vitamin D Receptor; EIF4E, Eukaryotic Translation Initiation Factor 4E; RAD54, homologue of S.Cerevisiae Rad54; JMJD2A, Jumanji Domain containing protein 2A; FRET, Fluorescence Resonance Energy
Transfer; IF, immunofluorescence; ELISA, Enzyme Linked Immuno-Sorbent Assay; rpS6, Small Ribosomal Protein 6; FP, Fluorescence Polarization; TR-FRET, Time Resolved FRET;HR,Homologous Recombination.
Figure 2. Performance of the network ensemble and virtual screening results. (A) Receiver operating characteristic plot of the
performance of 1 of the 10 networks in the trained ensemble showing results for each output neuron. One neuron each classified active
or inactive compounds. (B) Summed confusion matrix for the 10-network classifier. Numbers represent total compound number and
percentage of the training set falling in each quadrant as classified across all networks. Cohen’s κ = 0.65 for the ensemble. (C) Principal
component analysis of filtered virtual screening hits (total set in blue) and compounds selected after clustering on 3D pharmacophores
(red). Principal component analysis was performed in Matlab on 3D pharmacophores extracted using Canvas.
Neoplasia Vol. 17, No. 9, 2015 A Selective G1-Phase Benzimidazolone Inhibitor Bilsland et al. 707
708 A Selective G1-Phase Benzimidazolone Inhibitor Bilsland et al. Neoplasia Vol. 17, No. 9, 2015chemical spaces. Parameter scanning was again performed on this data
with 10-fold cross-validation. Best accuracy (Supplementary Figure
S4) was obtained with 2-layer networks having 20 neurons in the
hidden layer with 2 output neurons (Figure 1D) trained by scaled
conjugate gradient descent [23]. We finally selected an ensemble of
10 networks trained using the optimal parameter, compound, and
descriptor sets. A representative receiver operating characteristic plot
for one of these is shown in Figure 2A. The high area under the curve
of each output neuron indicates excellent classification of both active
and inactive compounds. The overall sensitivity and specificity of the
entire panel were 83.1% and 82.4%, respectively, for the “hit” output
neuron (Figure 2B). Overall accuracy was 82.7%, and Cohen’s κ =
0.65 indicated very good classification performance [35].
We used the trained ensemble to screen 2,086,587 structures with
weighting for specificity by application of a cutoff of 0.95 on the active
output neuron and 0.05 on the inactive output neuron, resulting in
17,278 virtual hits. To prioritize these, in silico physicochemical and
ADMET filters were applied (Supplementary Table S2). A total of
4929 compounds remained after filtering, and these were clustered on
3D pharmacophore fingerprints. A final set of 147 for cell-based
screening was obtained by sampling from these clusters (Figure 2C;
SMILES structures are given in Supplementary File 1).
Identification of a Highly Selective Benzimidazolone
SA-β-gal Inducer
The 147 compounds we r e f i r s t t e s t ed in MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
cell viability assays in HCT116 cells at 100 μM. Ninety-two
compounds showed at least 1.5-fold growth inhibition and were
taken into dose-response treatments (Supplementary Figure S4). Sixty
of the 92 compounds showed confirmed growth inhibition with IC50
b 100 μM (Figure 3A), and the top 50 of these with N60% growth
suppression at 100 μM were tested in a fluorometric SA-β-gal assay.
Each compound was tested initially at a single dose determined from
the MTT results to be the minimum concentration which achieved
maximum inhibition within the range tested. For example, this was
3.7 μM for compound EM10 and 33.3 μM for EM100 (Figure 3A,
top two rows).
The fluorometric SA-β-gal results are given in Figure 3B. In our
hands, the fluorometric assay has log-linear relation with the
proportion of HCT116 cells staining positive for SA-β-gal in the
standard staining assay in the range up to ~25% positive cells at
~1.5-fold fluorescence induction (Supplementary Figure S6). We
therefore imposed a cutoff of two-fold induction of signal relative to
untreated cells. Fifteen compounds achieved greater than two-fold
induction and were tested in colorimetric SA-β-gal staining
dose responses.
The most potent effects were observed in both assays with EM100.
SA-β-gal induction closely mirrored the inhibition of growth by
MTT for this compound (MTT IC50, 9.6 μM; SA-β-gal EC50, 8.3
μM) (Figure 3D). EM100 is the ChemBridge compound 20903630
(Figure 3C, hereafter referred to as CB-20903630). Interestingly, at
high concentration (33.3 μM), the compound was able to elicit
detectable SA-β-gal staining in almost all cells against a background of
extremely low (b1%) staining in untreated control cells (Figure 3E).
Furthermore, staining in the entire population was achieved without
observable loss of attachment, suggesting little or no cell death.
Therefore, CB-20903630 appeared highly selective in inducing a key
senescence marker.Structure-Activity and Cell Cycle Inhibition Effects of
Compound CB-20903630
To test preliminary SAR around CB-20903630, we searched
commercial vendor libraries, identifying close structural analogues
with a range of lipophilicities and functionalities, and obtained 10
structurally related analogues (Figure 4A). There were few commer-
cially available analogues which maintained the 4-methyl-6-cyclobutyl
motif present in CB-20903630, so we instead focused on analogues
retaining the benzimidazolone motif.
Within this set (compounds 101-110), we found a range of MTT
growth inhibition activities, with compound 101, containing the
1,2,4-triazine naphthyl group, possessing a respectable IC50 of 7.1
μM, in line with CB-20903630. Reassuringly, additional changes on
this portion of the molecules were also tolerated, with both saturated
(compounds 103 and 108) and unsaturated (compound 107) being
tolerated. In addition, the presence of basic (compound 109) and
neutral (compounds 102-106, 108, and 110) functionality indicates
that there is potential to further optimize this series.
Because CB-20903630 remained among the best of the set tested,
its identity and purity (N95%) were confirmed at resupply. We then
investigated its effects on cell-cycle effectors involved in mediating
arrest during senescence. HCT116 cells were treated for 48 hours in
the presence of DMSO or 10 μM CB-20903630. Cells were
harvested for Western blotting of cyclin B1, p21, CDK1, and
CDC25C (Figure 4B). Cyclin B1, CDK1, and expression of the short
isoform of CDC25C were all downregulated by CB-20903630
treatment, whereas levels of p21 were elevated (Figure 4B).
To confirm the cell cycle effects of the compound, we performed
propidium iodide FACS analysis in treated HCT116 cells.
Forty-eight–hour treatments at 20 μM were found to produce
more robust effects than 10 μM, so we retained this dose for further
growth-related assays. As shown in Figure 4C, CB-20903630
promoted a two-fold increase in G1 DNA content with a
concomitant reduction in S-phase. Notably, there was no observed
increase in the sub-G1 signal, suggesting that the compound does not
significantly promote apoptosis and growth inhibition is primarily
mediated through a G1 block.
We next compared growth inhibition of HCT116 with the
isogenic deletion variants HCT116-p53−/− and HCT116-p21−/−
(Figure 4D). The parental and the p53 deleted lines showed similar
profiles, suggesting that p53 is not essential for cell cycle arrest by the
compound. However, an approximately 1.5-fold reduction in
sensitivity was observed in the p21 deleted cells. Hence, p21 but
not p53 appears to play a role in the compound activity, in line with
Figure 4B.
To confirm selectivity, we tested CB-20903630 in the M30
Apoptosense assay which measures an apoptotic neo-epitope of
cleaved cytokeratin 18. CB-20903630 at 20 μM did not significantly
increase cleaved CK18. However, the cytotoxic agent etoposide
caused a 1.8-fold increase (Figure 4E, P b .01). Thus, CB-20903630
did not appear to induce substantial levels of apoptosis under these
conditions in HCT116 cells.
Accelerated senescence is associated with an inflammatory
phenotype characterized by secretion of a range of cytokines [6,7].
To investigate the inflammatory response of HCT116 cells, control
or treated cell supernatants were tested in a multiplex assay analyzing
the levels of 10 proinflammatory cytokines. Levels of most cytokines
were low (Supplementary Figure S7) with the exception of IL8
(Figure 4F). CB-20903630 did not induce a proinflammatory
Figure 3. Cell-based screening results and identification of CB-20903630. (A) MTT cell growth inhibition results for compounds showing
confirmed dose-dependent inhibition with IC50 b 100 μM. Heat maps were visualized in Tableau desktop. Numbers in each cell represent
mean fold of control for each concentration of compound. Mean ± SEM of three experiments. (B) Fluorometric SA-β-gal on the 50 most
potent MTT hits. Results are fold of vehicle-treated control. Two-fold activation of fluorescent signal was chosen as cutoff. Mean ± SEM
of two experiments. (C) Structure of CB-20903630. The structure was confirmed by nuclear magnetic resonance, and purity was N95% by
liquid chromatography. (D) Growth inhibition and SA-β-gal population-staining dose responses for CB-20903630. To clarify the shared
dose response, data shown for SA-β-gal are unstained cells at each dose (1 minus SA-β-gal positive). Mean ± SEM of three experiments
(MTT) or two experiments (SA-β-gal). (E) Representative micrographs showing SA-β-gal staining in untreated HCT116 cells or cells treated
at 33.3 μM.
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levels. Hence, despite its cell cycle effects, CB-20903630 did not
induce the “senescence-associated secretory phenotype.”We next treated HCT116 cells continuously with DMSO or
20 μM CB-20903630 twice weekly for 1 month to determine
cumulative population doublings with weekly counting (Figure 5A).
Figure 4. Structure-activity for the benzimidazolone scaffold and cell cycle effects of CB-20903630. (A) MTT SAR analysis of commercially
available related analogues identified in the Chembridge catalogue. Mean IC50 of three experiments is shown. (B) Western blotting
analysis of cell cycle effects in CB-20903630–treated HCT116 cells. Representative blots are shown. The experiment was performed
twice. (C) Propidium iodide FACS analysis of cell cycle phase in control or treated cells. A representative histogram is shown. The
experiment was performed three times. (D) MTT growth inhibition CB-20903630 dose-response in HCT116 or p53−/− and p21−/−
isogenic variants. Mean ± SEM of three experiments. (E) Apoptosense CK18 assay of CB-20903630 or etoposide treatment in HCT116
cells. Mean± SEM of three experiments (significance assessed by ANOVA: ns, not significant, **P b .01). (F) Suppression of IL-8 levels by
CB-20903630 in HCT116 cells. Mean ± SEM of three experiments (significance assessed by ANOVA: **P b .01).
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treatment. In contrast, treated cell growth was severely retarded, and
the cells underwent only 10.7 population doublings in total.
Therefore, CB-20903630 treatment produced sustained inhibition
of population growth.
We also examined CB-20903630 effects in an HCT116 spheroid
model developed by adjustment to serum-free culture. Suspension
cells were seeded for 5 days in the absence of treatment to allow
initiation of multicellular spheroids, then swapped into 20 μM
CB-20903630 or control medium (treatment day 0, Figure 5B), and
cultured for a further 4 days. Treatment was repeated after 2 days.
Compound was not removed between treatments.
Control spheroids significantly increased in volume in this period,
whereas treated spheroids remained small (Figure 5B, right panels).
Quantification of microscopic area of 50 individual spheroids in eachcondition showed a 3.5-fold difference (Figure 5C). Interestingly,
following second treatment, many single cells were observed in
treated flasks but not controls. In addition, treated spheroids were
fewer in number and less tightly aggregated. It is possible that cell
death pathways predominate under altered attachment.
Expression Profiling and Pathway Analysis of
CB-20903630 Activity
To investigate themechanismof action ofCB-20903630,we performed
microarray analysis using cDNA from cells treated for 48 hours with
DMSO or 10 μM CB-20903630. We identified differentially expressed
transcript IDs with greater than three-fold intensity change (p b 0.05)
between control and treated cells. Modeling in MetaCore [28] generated a
network of known direct interactions among the differentially expressed
genes. All direct interactions with cluster size ≥2 were included (Figure 6A).
Figure 5. Long-term growth effects of repeat treatment with CB-20903630 and inhibition of multicellular spheroid growth. (A) HCT116
cells weremaintained in culture and treated twice-weekly with CB-20903630 or vehicle. Cell numbers were counted weekly for calculation
of cumulative population doublings. Mean ± SEM of three experiments. (B) HCT116 cells were adapted to serum-free conditions to
generate a suspension line which grows as multicellular spheroids. Small spheroids were allowed to form in culture medium for 5 days
then treated twice with CB-20903630 or vehicle. Representative micrographs obtained during the treatment period are shown. (C)
Quantitation of mean area of 50 treated or control spheroids after 4 days of treatment with CB-20903630. Significance of population
difference was assessed by Wilcoxon rank sum test (**P b .001).
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proliferation were affected, including upregulation of Fra-2, DBP,
and C/EBP, whereas E2F2, Gli-1, MEIS2, PBX, and Sox4 were
downregulated. Interestingly, a number of secreted and membrane
proteins were also downregulated including CCL19, vasohibin 2,
semaphorins, fibulin-5, MMP9, BMP4, and ephrin A. These results
suggest that the compound may regulate a secretory program distinct
from the inflammatory markers investigated above. Clock genes
PER1 and PER3 were also differentially regulated, in line with a
previous study which found clock gene repression in vascular smooth
muscle cells undergoing telomere-dependent senescence [36]. Process
enrichment indicated that CB-20903630 promotes differential
expression on inflammatory and developmental signaling networks
as suggested by the model (Figure 6B).
CB-20903630 contains a kinase hinge-binding motif [37],
indicating that the compound may target a cell cycle–related kinase.
We generated expression profiles of IMR90 fibroblasts treated with
13 well-characterized kinase inhibitors (Supplementary Table S3)
most of which induce a senescence-associated heterochromatin foci–
like phenotype [49] and apoptosis and/or cell cycle responses. This
data set represents a range of senescence effects induced by different
pathway-specific agents in cells with an intact senescence response.
To compare the effects of CB-20903630, we also treated IMR90
with the compound and compared both HCT116 and IMR90
profiles with the other inhibitors. Responses were clustered on
significance of overlap in affected MetaCore process networks.
Numbers of significant process networks under each inhibitor
treatment were used to generate hypergeometric probabilities for
each pairwise comparison, which we used as an unweighted average
distance metric (Figure 6C).
EGFR inhibitor clustered with JNKIX. Cell cycle pathways, cell
adhesion, and developmental and cytoskeletal processes were affected
by this group. Two AKT inhibitors (AKTV and AKTVIII) are
present in the analysis, alongside two PI3K inhibitors (PI103 and
GDC0941). AKTV/GDC0941 clustered and the CB-20903630
process network profile in IMR90 cells also clustered in this group.
Adhesion, inflammation, development, and proteolysis processes are
strongly represented in this group. The AKTVIII profile was also
close to these in the analysis, whereas the other PI3K inhibitor PI103was more closely related to the PDGFR inhibitor; both of these had
very large process network profiles (52 and 59 networks affected,
respectively). MAPK inhibitor MK2A clustered with Src-family
inhibitor SU6656 and with AuroraII, primarily affecting DNA
damage, cell cycle, and apoptosis processes.
The CB-20903630 process network profile in HCT116 clustered
away from all others, possibly indicating that the compound
mechanism affects different pathways in normal versus cancer cells.
The profile in IMR90 appears to suggest similarity with agents
targeting the PI3K/AKT pathway. CB-20903630 profiles in IMR90
and HCT116 were partially overlapping because five of the eight
processes scoring as significant in HCT116 cells were also significant
in IMR90 cells (Figure 6, A and B, and Supplementary Figures S8
and S9). Inflammatory processes were also highly represented in
IMR90. However, IMR90 cells also scored highly in a range of
development and proteolysis processes shared by the PI3K/AKT
agents, making the observed profile more similar to these. Thus,
different pathways may be affected by the compound in normal
versus cancer cells.
To determine whether CB-20903630 is structurally related to existing
kinase inhibitors, we performed clustering analysis on 3D pharmaco-
phores comparing CB-20903630 alongside 527 known kinase inhibitors
using a self-organizing map (Figure 6D). CB-20903630 loaded with 15
other compounds on a neuron which did not cluster strongly with
neighbors. Examination of the structures showed prevalence of JNK2/3,
VEGFR2, and GSK3 inhibitors (Supplementary File 2). However,
CB-20903630 had little 2D similarity with these. Together, our results
suggest that CB-20903630 is a selective cell cycle inhibitor which appears
to be structurally novel.
Discussion
Cellular immortality is a hallmark of cancer and a near-universal
cancer target. However, recent clinical results suggest that telomerase
may prove a more refractory target than had been hoped in solid
tumors [38]. Multiple pathways regulate telomerase, and a variety of
backup mechanisms may exist facilitating escape from inhibition
[28,39]. On the other hand, strong interest in senescence induction as
an alternative target to reverse limitless replicative potential of cancer
cells has also emerged in recent years.
Figure 6. Microarray and structural analysis of CB-20903630. (A) Direct interactions network of differentially expressed genes in HCT116
cells treated with 10 μMCB-20903630. RNA samples fromDMSO versus compound-treated cells were profiled on Agilent whole genome
expression arrays. Differentially expressed gene lists were analyzed inMetaCore by the direct interactions algorithm to obtain the network
model. Green and red arrows indicate known activating or inhibitory interactions between entities, respectively. Red and blue circles
indicate upregulation and downregulation of expression relative to vehicle treatment, respectively. (B) Significant differentially affected
GeneGo process networks under CB-20903630 treatment in HCT116 cells obtained by enrichment analysis of differentially affected genes.
(C) Clustering of process network profiles with cumulative hypergeometric probability of pairwise overlap as the unweighted distance
metric. (D) SOM structural clustering of CB-20903630 and known kinase inhibitors (see Materials and Methods section for source of
comparator structures) after 200 training cycles. (Upper panel) Compound loadings: CB-20903630 and 15 other compounds loaded on the
highlighted neuron in the upper panel. Numbers indicate number of compounds on each neuron. (Lower panel) Visualization of neighbor
weights: the CB-20903630 neuron is not strongly clustered with its neighbors (darker bands indicate larger distances).
712 A Selective G1-Phase Benzimidazolone Inhibitor Bilsland et al. Neoplasia Vol. 17, No. 9, 2015We began with a strategy to match training compound sets to
the expression profile of telomere dysfunction. We identified a
target panel, optimized a neural network ensemble, and screened a2M-compound virtual library. Virtual hits were prioritized based
on ADMET filters and pharmacophore clustering to identify a
cell-based screening set, resulting in identification of
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of HCT116 cells and modulates cell cycle targets p21, cyclin B1,
CDC25C, and CDK1, causing a G1 blockade without observable
induction of cell death.
Preliminary SAR indicates scope for enhancement of
CB-20903630 activity. However, relatively few close commercial
analogues were found to be available, and we have therefore not
exhaustively investigated this aspect and focused instead on the
activity of CB-20903630. The growth inhibition effect appears to be
in part dependent on p21 but not p53 based on sensitivities of
isogenic HCT116 variants. In long-term treatments, the compound
severely repressed population doubling times and strongly repressed
growth in a multicellular spheroid model. The target of
CB-20903630 is unknown. However, expression and structural
clustering analysis suggest that the effects of the compound in normal
cells have similarity with agents targeting the PI3K/AKT pathway,
whereas in cancer cells, the effects diverged from other well
characterized cell cycle inhibitors.
Virtual screening has previously been used for the identification of
ligands for single targets [40]. In one recent example, the compound
6,6”-biapigenin was identified as a novel inhibitor of the NEDD8
activating enzyme (NAE) which is required for NEDDylation of a
wide range of cellular targets. A previously identified NAE inhibitor
showed broad activity against cancer cell lines, and the authors used
molecular docking against a quaternary complex comprising the NAE
subunits APPBP1 and UBA3 as well as its NEDD8 and ATP
substrates to identify the new compound which showed low
micromolar activity in Caco-2 cells [41]. Multitarget approaches
such as that described here have not been widely investigated,
although a recent study reported use of combinatorial support vector
machine classifiers to identify dual-specificity ligands for a range of
kinase pairs [42]. Furthermore, “inverse docking” in which individual
compounds are docked against target panels has been suggested as a
potentially powerful tool for compound repositioning strategies to
complement existing pipelines in the pharmaceutical industry [43].
Our results suggest that virtual screening focused on target panels may
also provide a useful approach for the identification of phenotype-
focused libraries.
Ultimately, development of senescence therapeutics will require
greater understanding of the regulation of senescence signaling
networks. CB-20903630 is an interesting tool compound which
appears to be a highly selective cell cycle inhibitor. The compound
may therefore be a useful probe to identify new candidate markers
and mechanisms associated with senescence and cell cycle responses.
However, broad knowledge of the scaffold types that are able to
regulate senescence pathways will also be required to identify a range
of selective agents. In this paper, we identified a kinase-like scaffold by
restricting our training set and library to “drug-like” chemical space.
However, other regions of chemical space might also be worthy of
consideration, such as natural product libraries or novel organome-
tallic agents [44,45]. As in the current report, virtual screening might
also provide an extremely useful tool to probe these novel library types
in future studies.
Materials and Methods
Training Library Assembly and Neural Network Optimization
Training compounds were identified in confirmatory PubChem
bioassay entries reported in Table 1 or from in-house data in the caseof p21. All neural network optimization on neuron number, number
of hidden layers, and training rule was performed using the Matlab
neural network toolbox (Mathworks, Natick, MA). Ten-fold cross-
validation was performed on each parameter set. The overall
optimization workflow is shown in Supplementary Figure S2.
Chemical descriptor sets were obtained using PaDEL Descriptor
[33] and PowerMV [32].
Highly correlated descriptors and those with a variance of 0
were excluded, and the smaller representative set of descriptors
was chosen using the Feature Selection option of the Canvas
program [46,47] (Canvas, version 2.0; Schrödinger, LLC, New
York, NY). 3D Pharmacophore fingerprints were also calculated
in Canvas and ADME/Tox properties (Supplementary Table S2)
in QikProp (QikProp, version 4.0; Schrödinger, LLC, New York,
NY, 2014).
Cell Lines and Compounds
The cells used were HCT116 colorectal cancer cells, their p53 and
p21 deleted isogenic derivatives, and IMR90 fibroblasts. One hundred
forty-seven virtual hits were selected based on the clustering analysis
using 3D pharmacophore fingerprints. Compounds were initially
sourced through E-Molecules (Stevenage, UK). CB-20903630 resup-
ply and related analogues were obtained fromChemBridge (San Diego,
CA). Structure was confirmed by nuclear magnetic resonance, and
purity was confirmed by liquid chromatography/mass spectrometry. All
other signal transduction inhibitors reported were obtained from
Millipore (Supplementary Table S3). GRN163L was kindly provided
by the Geron Corporation (Menlo Park, CA).
MTT, Fluorescent SA-β-gal, and M30 Assays
For MTT assay, cells were treated twice over 48 hours with
compounds and then incubated for a further 3 days before MTT
assay (MTT supplied by Sigma, Dorset, UK). MTT reduction assays
were performed using Softmax Pro software (Molecular Devices Ltd.,
Wokingham, UK). All experiments were repeated three times. Heat
maps were generated in Tableau Desktop (Tableau Software, Seattle,
WA). Fluorescent SA-β-gal assays were performed using the 96-well
kit by Cell Biolabs (San Diego, CA). Cells were seeded overnight
before 48-hour compound treatments. Five micrograms of protein
was incubated in duplicate with assay buffer for 3 hours. Fluorescence
was measured using a Safire plate reader (Tecan Group, Männedorf,
Switzerland). All experiments were repeated twice. In colorimetric
SA-β-gal staining assays, cells were fixed in gluteraldehyde and stained
in the dark overnight with X-gal at pH 6. At least 500 cells in 5
random fields were counted for microscopic evaluation of proportions
of stained cells in any treatment condition.
For M30 assay, cells were seeded in triplicate wells of 96-well plates
overnight before addition of compound. Cells were treated for 2 days
with compounds or vehicle then harvested. ELISA was performed on
supernatants according the manufacturer’s instructions (VLVbio,
Nacka, Sweden) with quantification using Softmax Pro software
(Molecular Devices Ltd., Wokingham, UK). Experiments were
repeated three times.
Western Blotting
Twenty micrograms of protein was separated by SDS-PAGE,
blotted onto polyvinylidene difluoride (Millipore, Watford, UK), and
blocked overnight in PBS-T containing 5% nonfat dried milk.
Antibodies were cyclin B1 (4135), p21 (2946), CDK1 (9112), and
714 A Selective G1-Phase Benzimidazolone Inhibitor Bilsland et al. Neoplasia Vol. 17, No. 9, 2015CDC25C (4688), all obtained from New England Biolabs UK
(Hitchin, UK). Primary antibodies were detected with HRP-
conjugated secondary. HRP was detected using ECL detection
reagents (Amersham Pharmacia, Buckinghamshire, UK). Experi-
ments were performed at least twice.
FACS Analysis
Treated cells were fixed in 70% ethanol and stained with 0.05
mg/ml of propidium iodide solution containing 1 mg/ml of RNAse
A (both obtained from Life Technologies, Paisley, UK) and 0.3%
Tween-20 (Sigma, Dorset, UK). FACS was performed on a
FACSverse instrument (BD Biosciences, Oxford, UK). Experi-
ments were performed three times.
Microarray Processing
RNA was labeled and amplified using the one-color microarray
gene expression analysis protocol (Agilent Technologies, Santa Clara,
CA), hybridized to Agilent whole human genome 4 × 44k Agilent
whole human genome microarrays, and incubated for 17 hours at
60°C in a hybridization oven. Arrays were washed on a magnetic
stirrer using Agilent wash buffers. Slides were scanned on an Agilent
microarray scanner at 5-μm resolution, photomultiplier tube (PMT)
gain at 100% and 10%. The extended dynamic range setting was
corrected for saturation. Kinase inhibitor treatments in IMR90 were
performed twice. CB-20903630 treatment of HCT116 was
performed three times, but in IMR90 cells, only two independent
experiments were performed because of compound availability. The
data set has been submitted to the Gene Expression Omnibus with
accession number GSE72621.
Microarray Data Analysis
Microarray data were extracted using Agilent Feature Extraction
software (Agilent Technologies, Santa Clara, CA). All array data
were analyzed in GeneSpring for normalization and statistical
analysis (Agilent Technologies, Santa Clara, CA). Intraarray
normalization was carried out using the 75th percentile for each
microarray. Significant differences in expression between control
and treated cells were determined using unpaired t test. IDs with
greater than three-fold intensity change, P b .05, were selected for
further analysis.
Process Profiles, Network Modeling, and Structural Clustering
Differentially expressed genes were analyzed in MetaCore
(Thomson Reuters, New York, NY) using enrichment analysis by
GeneGo process networks [27]. Probability of overlap was scored for
each gene list tested against all process networks in the MetaCore
database. Network analyses were performed using the GeneGo direct
interactions algorithm [29]. For process network clustering, cumu-
lative hypergeometric probability of pairwise overlap between process
network profiles was calculated. Dendrograms were generated from
the matrix of pairwise probabilities for all comparisons using
unweighted average distances in Matlab (Mathworks, Natick, MA).
For structural clustering, 3D pharmacophores were calculated in
Canvas. Included structures were CB-20903630 and 527 kinase
inhibitors pooled from the Millipore Inhibitor Select 384-well panel
(#539743) and from the GSK Published Kinase Inhibitor Set [48].
The finger prints were clustered on a 10 × 10 self-organizing map in
Matlab using 200 training iterations. Compounds loading with
CB-20903630 are given in Supplementary File 2.Statistical Analysis
All statistical analyses were performed in Microsoft Excel or Matlab.
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